X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
chemotherapy (7) 7
aged (6) 6
female (6) 6
humans (6) 6
index medicus (6) 6
male (6) 6
middle aged (6) 6
antineoplastic combined chemotherapy protocols - therapeutic use (5) 5
cancer (5) 5
lung cancer, non-small cell (5) 5
lung neoplasms - drug therapy (5) 5
lung neoplasms - mortality (5) 5
cancer therapies (4) 4
carboplatin (4) 4
carcinoma, non-small-cell lung - drug therapy (4) 4
carcinoma, non-small-cell lung - mortality (4) 4
cisplatin - administration & dosage (4) 4
disease-free survival (4) 4
hematology, oncology and palliative medicine (4) 4
lung cancer (4) 4
neoplasm staging (4) 4
oncology (4) 4
research (4) 4
adult (3) 3
aged, 80 and over (3) 3
antibodies, monoclonal - administration & dosage (3) 3
antineoplastic agents (3) 3
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
carcinoma, non-small-cell lung - pathology (3) 3
cetuximab (3) 3
clinical trials (3) 3
growth-factor receptor (3) 3
kaplan-meier estimate (3) 3
lung neoplasms - pathology (3) 3
metastasis (3) 3
mutation (3) 3
oncology, experimental (3) 3
survival (3) 3
treatment outcome (3) 3
tumors (3) 3
abridged index medicus (2) 2
antibodies, monoclonal - adverse effects (2) 2
antimitotic agents (2) 2
antineoplastic agents - therapeutic use (2) 2
bevacizumab (2) 2
carboplatin - administration & dosage (2) 2
care and treatment (2) 2
cisplatin (2) 2
combination (2) 2
docetaxel (2) 2
double-blind method (2) 2
drug administration schedule (2) 2
drug therapy (2) 2
erlotinib (2) 2
expression (2) 2
iii trial (2) 2
immunotherapy (2) 2
medicine, general & internal (2) 2
metaanalysis (2) 2
monoclonal antibodies (2) 2
motivation (2) 2
neutropenia (2) 2
paclitaxel (2) 2
patients (2) 2
pharmaceutical industry (2) 2
proportional hazards models (2) 2
quality of life (2) 2
quality-of-life (2) 2
receptor, epidermal growth factor - antagonists & inhibitors (2) 2
solid tumors (2) 2
studies (2) 2
survival analysis (2) 2
survival rate (2) 2
therapy (2) 2
1st-line treatment (1) 1
[sdv.spee]life sciences [q-bio]/santé publique et épidémiologie (1) 1
acne (1) 1
adolescent (1) 1
advanced non-small cell lung cancer (1) 1
age factors (1) 1
analysis (1) 1
anemia - etiology (1) 1
antibodies, monoclonal (1) 1
antibodies, monoclonal - therapeutic use (1) 1
antibodies, monoclonal, humanized (1) 1
antibody (1) 1
antigens (1) 1
antigens, cd - analysis (1) 1
antigens, differentiation, t-lymphocyte - analysis (1) 1
antineoplastic agents - adverse effects (1) 1
antineoplastic combined chemotherapy protocols (1) 1
apoptosis (1) 1
association (1) 1
bayesian analysis (1) 1
bevacizumab - administration & dosage (1) 1
biomarkers (1) 1
biomarkers, tumor - blood (1) 1
brazil (1) 1
cancer vaccines - adverse effects (1) 1
cancer vaccines - therapeutic use (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 7, pp. 763 - 774
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 6, pp. 521 - 529
Journal Article
Lancet, The, ISSN 0140-6736, 2009, Volume 373, Issue 9674, pp. 1525 - 1531
Summary Background Use of cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), has the potential to increase survival in... 
Internal Medicine | GROWTH-FACTOR RECEPTOR | 1ST-LINE TREATMENT | MEDICINE, GENERAL & INTERNAL | CARBOPLATIN | GEFITINIB | THERAPY | CISPLATIN | COMBINATION | GEMCITABINE | ERLOTINIB | PACLITAXEL | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Receptor, Epidermal Growth Factor - drug effects | Antibodies, Monoclonal - therapeutic use | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Vinblastine - administration & dosage | Cisplatin - administration & dosage | Young Adult | Antibodies, Monoclonal, Humanized | Vinblastine - analogs & derivatives | Aged, 80 and over | Adult | Female | Cetuximab | Carcinoma, Non-Small-Cell Lung - pathology | Proportional Hazards Models | Survival Rate | Treatment Outcome | Receptor, Epidermal Growth Factor - analysis | Carcinoma, Non-Small-Cell Lung - mortality | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Survival Analysis | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Chemotherapy | Research | Comparative analysis | Lung cancer, Non-small cell | Drug therapy | Health aspects | Cancer | Drugs | Studies | Data analysis | Lung cancer | Acne | Monoclonal antibodies | Clinical medicine | Kinases | Quality of life | Index Medicus | Abridged Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 3, pp. 328 - 337
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 2, pp. 212 - 223
Summary Background MUC1 is a tumour-associated antigen expressed by many solid tumours, including non-small-cell lung cancer. TG4010 is a modified vaccinia... 
Hematology, Oncology and Palliative Medicine | ONCOLOGY | MVA-MUC1-IL2 | PROSTATE-CANCER | VACCINE | Predictive Value of Tests | Carcinoma, Non-Small-Cell Lung - chemistry | Humans | Middle Aged | Fatigue - etiology | Male | Cisplatin - administration & dosage | Antigens, CD - analysis | Antigens, Differentiation, T-Lymphocyte - analysis | Neutropenia - etiology | Cancer Vaccines - therapeutic use | Receptors, IgG - analysis | Mucin-1 - analysis | Lectins, C-Type - analysis | Female | Paclitaxel - administration & dosage | Lymphocytes - chemistry | Anemia - etiology | Bevacizumab - administration & dosage | Double-Blind Method | Lung Neoplasms - chemistry | Lymphocyte Activation | CD56 Antigen - analysis | Deoxycytidine - administration & dosage | Erlotinib Hydrochloride - administration & dosage | Carboplatin - administration & dosage | Cancer Vaccines - adverse effects | Lung Neoplasms - therapy | Immunotherapy - adverse effects | Biomarkers, Tumor - blood | Disease-Free Survival | Carcinoma, Non-Small-Cell Lung - therapy | Membrane Glycoproteins - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pemetrexed - administration & dosage | Aged | Membrane Glycoproteins - adverse effects | Deoxycytidine - analogs & derivatives | Antigens | Fc receptors | Hospitals | Interleukins | Immunotherapy | Mucins | Clinical trials | Product development | Lung cancer, Non-small cell | Analysis
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2018, Volume 379, Issue 23, pp. 2220 - 2229
Journal Article
Lung Cancer, ISSN 0169-5002, 2006, Volume 53, Issue 2, pp. 231 - 239
Patients with advanced non-small cell lung cancer (NSCLC) do not have curative treatment options; therefore, treatments should prolong survival and improve... 
Docetaxel | Carboplatin | Advanced non-small cell lung cancer | Patient-reported outcomes | Cisplatin | Vinorelbine | Symptoms | Quality of life | Antimitotic agents | Chemotherapy | Oncology, Experimental | Respiratory tract diseases | Respiratory agents | Research | Universities and colleges | Lung cancer, Non-small cell | Antineoplastic agents | Cancer
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.